Published in Gene Therapy Weekly, October 20th, 2005
The alliance has focused on the synergistic application of LSBC's and ICON's patented gene expression and biomanufacturing resources with the goal of developing and commercializing a product for enzyme replacement therapy, the manufacture of which by conventional technologies has proven difficult and expensive.
Both ICON and LSBC biomanufacture their own and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.